Toggle navigation

Eric Weinhandl, PhD, MS

Adjunct Assistant Professor
University of Minnesota College of Pharmacy

Clinical Epidemiologist and Statistician
NxStage Medical, Inc.

Eric Weinhandl is an epidemiologist with about 14 years of research experience in chronic kidney disease, mostly regarding dialysis and pharmaceuticals. Eric worked at the United States Renal Data System (USRDS) Coordinating Center between 2004 and 2014 and has conducted studies with Amgen, Baxter, DaVita, NxStage, Sigma Tau, and the Peer Kidney Care Initiative.

Articles By Eric Weinhandl, PhD, MS

When is More Frequent Hemodialysis Beneficial?

In 2017, Medicare Administrative Contractors (MACs) began to promulgate draft local coverage determinations that include restrictive language regarding Medicare reimbursement for additional hemodialysis sessions. An important element of the draft determinations is medical justification, or the clinical conditions that constitute evidence-based rationale for the prescription of more frequent hemodialysis. Suri and Kliger, who were both… Read More

ACE Inhibitors or ARBs: Which to Prescribe?

Many dialysis patients, including patients on frequent home hemodialysis, have been diagnosed with heart failure. In one large study, 31% of patients who initiated home hemodialysis already had heart failure.1 One of the cornerstones of pharmacologic therapy for heart failure is renin-angiotensin system blockade, which may be achieved with either angiotensin-converting enzyme (ACE) inhibitors or angiotensin… Read More

Standardized Kt/V on Home Hemodialysis: Does It Matter?

Hemodialysis adequacy has historically been assessed through the lens of Kt/V. Standardized Kt/V is a metric that specifically permits comparisons of urea clearance among heterogeneous hemodialysis schedules. Current clinical practice guidelines from the Kidney Disease Outcomes Quality Initiative (KDOQI) suggest a target standardized Kt/V of 2.3, and a minimal standardized Kt/V of 2.1.1 In principle,… Read More

  • Stay Current

    Receive email updates on trends, findings, and opinions related to more frequent hemodialysis.
  • We will not send or sell your information to any 3rd parties.
  • This field is for validation purposes and should be left unchanged.